Nexplanon (Etonogestrel)

Etonogestrel released from the implant suppresses the luteinizing hormone surge, which blocks ovulation. It also thickens cervical mucus, making it difficult for sperm to travel, and alters the endometrium, creating an environment unsuitable for implantation.

Nexplanon is supplied as a single 68 mg subdermal implant. The exact dosing schedule, including insertion and removal timing, is determined by the prescribing healthcare professional based on clinical guidelines.

Nexplanon is classified as pregnancy category X, meaning it must not be used by women who are pregnant. Women should use an alternative method if they become pregnant. Limited data exist for breastfeeding, and a healthcare provider should assess risks versus benefits.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and necessary import documentation.

Compared with daily oral pills, Nexplanon offers higher typical‑use effectiveness and eliminates the need for daily adherence. Unlike injectable progestins, it requires only a single insertion for up to three years, providing greater convenience and consistent hormone levels.

Nexplanon should be stored at ambient temperature, below 25 °C, in its original sealed packaging. Protect the device from moisture, direct sunlight and extreme temperatures to maintain its stability until the time of insertion.

A qualified healthcare professional inserts the Nexplanon implant subdermally in the inner side of the upper arm using a sterile applicator. The procedure is minimally invasive, performed in an outpatient setting, and the implant remains in place for up to three years before removal or replacement.

Serious risks include rare but potentially life‑threatening events such as deep vein thrombosis, pulmonary embolism, severe allergic reactions, and infection at the insertion site. Users should seek immediate medical attention if they experience unexplained swelling, severe pain, shortness of breath, or signs of an allergic response.

Nexplanon is contraindicated in women who are pregnant, have a known hypersensitivity to etonogestrel or any component of the device, have active breast cancer, or have a history of thromboembolic disorders without appropriate medical evaluation. A thorough medical assessment is required before insertion.